Publications
Print PDF
Biosimilar Guidances: Broader Populations Permitted; More Immunogenicity Requested
May 18, 2015
Brenda Sanburg
The Pink Sheet

Axinn Counsel Stacie Ropka was quoted in The Pink Sheet’s article, “Biosimilar Guidances: Broader Populations Permitted; More Immunogenicity Requested." The Pink Sheet is produced by Pharma & Med Tech Business Intelligence.

Click here to access the article. A subscription is required.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.